Following people with heart disease caused by AL amyloidosis
Observes patients with AL amyloidosis heart disease on their current treatment over time.
Plain-language title generated from the registry record
Registry title: Clinical Study for AL-CM
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with cardiac amyloidosis caused by immunoglobulin light chains (AL-CM) at one named hospital. It tracks treatment effect and long-term follow-up.
- Age
- 18-90 years in the criteria; the registry lists 18 to 80 years.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of AL-CM (light chain amyloidosis affecting the heart). No stage is given.
Main reasons for not taking part
- Cannot understand the trial or cannot cooperate with the investigators
- Unwilling to fill in the informed consent form
- Unwilling to follow the study visits
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04924998, who can take part
Where in China
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT04924998
- Record updated
- 31 January 2023
- Original description
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.Read full original descriptionShow less
Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
Inclusion: Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine; Patients have the ability to understand the test, can cooperate with investigators.
Exclusion: Unable to understand or unwilling to fill in informed consent forms or follow visitors.